Vericel Corporation
Vericel Corporation (VCEL) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · VCEL · as of Jun 9, 2026
Key Statistics
Explore Vericel Corporation Data
vcel stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 14 · Buy rate: 64.3%
The VCEL analyst consensus is Buy, based on ratings from 14 Wall Street analysts over the past 3 months. The average 12-month price target is $52.67, representing +47.25% upside from the current price of $35.77.
Competitors & Peers
vcel competitorsVCEL
AUPH
EWTX
GPCR
HRMY
MESOStock Performance
Full HistoryAbout Vericel Corporation
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments.…
what is vericel corporation · vcel stock overview · vericel corporation company profile · who is vericel corporation ceo · vcel NASDAQ · vericel corporation headquarters · vericel corporation business segments
About Stock Overview & Key Data
Vericel Corporation (VCEL) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Feb 4, 1997. As of the latest trading session, VCEL stock price is $35.77, with a market capitalization of $1.8B. The stock has returned -18.37% over the past 12 months and -0.67% year-to-date.
According to 14 Wall Street analysts, the consensus rating for Vericel Corporation stock is Buy, with an average 12-month price target of $52.67. In fiscal year 2025, Vericel Corporation reported revenue of $276.3M and net income of $16.5M. For detailed data — including Vericel Corporation revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Vericel Corporation (VCEL) stock price is $35.77. The stock is traded on NASDAQ under the ticker symbol VCEL. The 52-week range is $28.95 – $45.97.